| Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 1475 | 2015 |
| Poised epigenetic states and acquired drug resistance in cancer R Brown, E Curry, L Magnani, CS Wilhelm-Benartzi, J Borley Nature Reviews Cancer 14 (11), 747-753, 2014 | 315 | 2014 |
| A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic-and molecular-phenotypes of epithelial ovarian cancer H Lu, M Arshad, A Thornton, G Avesani, P Cunnea, ED Curry, F Kanavati, ... Nature communications 10 (1), 764, 2019 | 154 | 2019 |
| LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression M Mura, TG Hopkins, T Michael, N Abd-Latip, J Weir, E Aboagye, F Mauri, ... Oncogene 34 (39), 5025-5036, 2015 | 139 | 2015 |
| Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis K van Veldhoven, S Polidoro, L Baglietto, G Severi, C Sacerdote, ... Clinical epigenetics 7, 1-12, 2015 | 117 | 2015 |
| Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells N Chapman-Rothe, E Curry, C Zeller, D Liber, E Stronach, H Gabra, ... Oncogene 32 (38), 4586-4592, 2013 | 96 | 2013 |
| HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer H Brunton, G Caligiuri, R Cunningham, R Upstill-Goddard, UM Bailey, ... Cell reports 31 (6), 2020 | 89 | 2020 |
| Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells E Curry, I Green, N Chapman-Rothe, E Shamsaei, S Kandil, FL Cherblanc, ... Clinical epigenetics 7, 1-12, 2015 | 72 | 2015 |
| RIP140 represses the “brown-in-white” adipocyte program including a futile cycle of triacyclglycerol breakdown and synthesis E Kiskinis, L Chatzeli, E Curry, M Kaforou, A Frontini, S Cinti, G Montana, ... Molecular endocrinology 28 (3), 344-356, 2014 | 63 | 2014 |
| Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors G Nteliopoulos, A Bazeos, S Claudiani, G Gerrard, E Curry, R Szydlo, ... Haematologica 104 (12), 2400, 2019 | 49 | 2019 |
| Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis E Curry, C Zeller, N Masrour, DK Patten, J Gallon, CS Wilhelm-Benartzi, ... Cancer Research 78 (6), 1383-1391, 2018 | 41 | 2018 |
| Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours A Browne, R Sriraksa, T Guney, N Rama, S Van Noorden, E Curry, ... Cytokine 64 (1), 413-421, 2013 | 38 | 2013 |
| MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data S Rana, GN Valbuena, E Curry, CL Bevan, HC Keun British journal of cancer 126 (3), 502-513, 2022 | 37 | 2022 |
| Dynamic CpG methylation delineates subregions within super-enhancers selectively decommissioned at the exit from naive pluripotency E Bell, EW Curry, W Megchelenbrink, L Jouneau, V Brochard, RA Tomaz, ... Nature communications 11 (1), 1112, 2020 | 29 | 2020 |
| Dose-finding quantitative 18F-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecologic malignancies H Gungor, A Saleem, S Babar, R Dina, MA El-Bahrawy, E Curry, N Rama, ... Journal of Nuclear Medicine 56 (12), 1828-1835, 2015 | 27 | 2015 |
| A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 … A Cheraghchi-Bashi, CA Parker, E Curry, JF Salazar, H Gungor, ... Oncotarget 6 (39), 41736, 2015 | 26 | 2015 |
| WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response S Janczar, J Nautiyal, Y Xiao, E Curry, M Sun, E Zanini, AJW Paige, ... Cell death & disease 8 (7), e2955-e2955, 2017 | 23 | 2017 |
| Jmjd2c facilitates the assembly of essential enhancer-protein complexes at the onset of embryonic stem cell differentiation RA Tomaz, JL Harman, D Karimlou, L Weavers, L Fritsch, T Bou-Kheir, ... Development 144 (4), 567-579, 2017 | 23 | 2017 |
| Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures EWJ Curry, EA Stronach, NR Rama, YYP Wang, H Gabra, MA El-Bahrawy Modern Pathology 27 (3), 433-442, 2014 | 23 | 2014 |
| Tumor mutational landscape is a record of the pre-malignant state K Kübler, R Karlić, NJ Haradhvala, K Ha, J Kim, M Kuzman, W Jiao, ... BioRxiv, 517565, 2019 | 22 | 2019 |
